Table of Contents Author Guidelines Submit a Manuscript
Neural Plasticity
Volume 2015 (2015), Article ID 396908, 10 pages
http://dx.doi.org/10.1155/2015/396908
Research Article

α7 Nicotinic Receptor Promotes the Neuroprotective Functions of Astrocytes against Oxaliplatin Neurotoxicity

Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Pharmacology and Toxicology Section, University of Florence, 50139 Florence, Italy

Received 23 March 2015; Revised 19 May 2015; Accepted 20 May 2015

Academic Editor: Nicola Maggio

Copyright © 2015 Lorenzo Di Cesare Mannelli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Kannarkat, E. E. Lasher, and D. Schiff, “Neurologic complications of chemotherapy agents,” Current Opinion in Neurology, vol. 20, no. 6, pp. 719–725, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Wolf, D. Barton, L. Kottschade, A. Grothey, and C. Loprinzi, “Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies,” European Journal of Cancer, vol. 44, no. 11, pp. 1507–1515, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. N. C. Miltenburg and W. Boogerd, “Chemotherapy-induced neuropathy: a comprehensive survey,” Cancer Treatment Reviews, vol. 40, no. 7, pp. 872–882, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Weickhardt, K. Wells, and W. Messersmith, “Oxaliplatin-induced neuropathy in colorectal cancer,” Journal of Oncology, vol. 2011, Article ID 201593, 7 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Grothey, D. A. Nikcevich, J. A. Sloan et al., “Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7,” Journal of Clinical Oncology, vol. 29, no. 4, pp. 421–427, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. M. W. Saif and J. Reardon, “Management of oxaliplatin-induced peripheral neuropathy,” Journal of Therapeutics and Clinical Risk Management, vol. 1, no. 4, pp. 249–258, 2014. View at Google Scholar
  7. K. K. Baek, J. Lee, S. H. Park et al., “Oxaliplatin-induced chronic peripheral neurotoxicity: a prospective analysis in patients with colorectal cancer,” Cancer Research and Treatment, vol. 42, no. 4, pp. 185–190, 2010. View at Publisher · View at Google Scholar
  8. A. Avan, T. J. Postma, C. Ceresa et al., “Platinum-induced neurotoxicity and preventive strategies: past, present, and future,” The Oncologist, vol. 20, no. 4, pp. 411–432, 2015. View at Publisher · View at Google Scholar
  9. L. Di Cesare Mannelli, M. Zanardelli, P. Failli, and C. Ghelardini, “Oxaliplatin-induced neuropathy: oxidative stress as pathological mechanism. Protective effect of silibinin,” Journal of Pain, vol. 13, no. 3, pp. 276–284, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. D. L. Hershman, C. Lacchetti, R. H. Dworkin et al., “Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline,” Journal of Clinical Oncology, vol. 32, no. 18, pp. 1941–1967, 2014. View at Publisher · View at Google Scholar
  11. L. Di Cesare Mannelli, A. Pacini, L. Bonaccini, M. Zanardelli, T. Mello, and C. Ghelardini, “Morphologic features and glial activation in rat oxaliplatin-dependent neuropathic pain,” The Journal of Pain, vol. 14, no. 12, pp. 1585–1600, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Di Cesare Mannelli, A. Pacini, L. Micheli, A. Tani, M. Zanardelli, and C. Ghelardini, “Glial role in oxaliplatin-induced neuropathic pain,” Experimental Neurology, vol. 261, pp. 22–33, 2014. View at Publisher · View at Google Scholar
  13. E. D. Milligan and L. R. Watkins, “Pathological and protective roles of glia in chronic pain,” Nature Reviews Neuroscience, vol. 10, no. 1, pp. 23–36, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Boivin, I. Pineau, B. Barrette et al., “Toll-like receptor signaling is critical for Wallerian degeneration and functional recovery after peripheral nerve injury,” The Journal of Neuroscience, vol. 27, no. 46, pp. 12565–12576, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. M. S. Thomsen and J. D. Mikkelsen, “The α7 nicotinic acetylcholine receptor complex: one, two or multiple drug targets?” Current Drug Targets, vol. 13, no. 5, pp. 707–720, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. K. T. Dineley, A. A. Pandya, and J. L. Yakel, “Nicotinic ACh receptors as therapeutic targets in CNS disorders,” Trends in Pharmacological Sciences, vol. 36, no. 2, pp. 96–108, 2015. View at Publisher · View at Google Scholar
  17. L. Di Cesare Mannelli, A. Pacini, C. Matera et al., “Involvement of α7 nAChR subtype in rat oxaliplatin-induced neuropathy: effects of selective activation,” Neuropharmacology, vol. 79, pp. 37–48, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. A. L. Bodnar, L. A. Cortes-Burgos, K. K. Cook et al., “Discovery and structure-activity relationship of quinuclidine benzamides as agonists of alpha7 nicotinic acetylcholine receptors,” Journal of Medicinal Chemistry, vol. 48, no. 4, pp. 905–908, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Hajós, R. S. Hurst, W. E. Hoffmann et al., “The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 312, no. 3, pp. 1213–1222, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Malysz, J. H. Grønlien, D. B. Timmermann et al., “Evaluation of alpha7 nicotinic acetylcholine receptor agonists and positive allosteric modulators using the parallel oocyte electrophysiology test station,” Assay and Drug Development Technologies, vol. 7, no. 4, pp. 374–390, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Di Cesare Mannelli, M. Zanardelli, P. Failli, and C. Ghelardini, “Oxaliplatin-induced oxidative stress in nervous system-derived cellular models: could it correlate with in vivo neuropathy?” Free Radical Biology and Medicine, vol. 61, pp. 143–150, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. K. D. McCarthy and J. de Vellis, “Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue,” Journal of Cell Biology, vol. 85, no. 3, pp. 890–902, 1980. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Di Cesare Mannelli, D. Bani, A. Bencini et al., “Therapeutic effects of the superoxide dismutase mimetic compound MnIIMe2DO2A on experimental articular pain in rats,” Mediators of Inflammation, vol. 2013, Article ID 905360, 11 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. H. R. Quintá and M. D. Galigniana, “The neuroregenerative mechanism mediated by the Hsp90-binding immunophilin FKBP52 resembles the early steps of neuronal differentiation,” British Journal of Pharmacology, vol. 166, no. 2, pp. 637–649, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Jana and K. Pahan, “Fibrillar amyloid-β-activated human astroglia kill primary human neurons via neutral sphingomyelinase: implications for Alzheimer's disease,” Journal of Neuroscience, vol. 30, no. 38, pp. 12676–12689, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Cavaletti, G. Tredici, M. G. Petruccioli et al., “Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat,” European Journal of Cancer, vol. 37, no. 18, pp. 2457–2463, 2010. View at Google Scholar
  27. M. Zanardelli, L. Micheli, L. Cinci, P. Failli, C. Ghelardini, and L. Di Cesare Mannelli, “Oxaliplatin neurotoxicity involves peroxisome alterations. PPARγ agonism as preventive pharmacological approach,” PLoS ONE, vol. 9, no. 7, Article ID e102758, 2014. View at Publisher · View at Google Scholar
  28. S. S. Jacobs, E. Fox, C. Dennie, L. B. Morgan, C. L. McCully, and F. M. Balis, “Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates,” Clinical Cancer Research, vol. 11, no. 4, pp. 1669–1674, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. S. S. Jacobs, C. L. McCully, R. F. Murphy, J. Bacher, F. M. Balis, and E. Fox, “Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates,” Cancer Chemotherapy and Pharmacology, vol. 65, no. 5, pp. 817–824, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. O. Elekes, K. Venema, F. Postema, R. Dringen, B. Hamprecht, and J. Korf, “Evidence that stress activates glial lactate formation in vivo assessed with rat hippocampus lactography,” Neuroscience Letters, vol. 208, no. 1, pp. 69–72, 1996. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Chen, E. A. Oyarzabal, Y. Sung et al., “Microglial regulation of immunological and neuroprotective functions of astroglia,” Glia, vol. 63, no. 1, pp. 118–131, 2015. View at Publisher · View at Google Scholar
  32. H. Kajihara, E. Tsutsumi, A. Kinoshita, J. Nakano, K. Takagi, and S. Takeo, “Activated astrocytes with glycogen accumulation in ischemic penumbra during the early stage of brain infarction: immunohistochemical and electron microscopic studies,” Brain Research, vol. 909, no. 1-2, pp. 92–101, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. J. R. Goss, M. E. O'Malley, L. Zou, S. D. Styren, P. M. Kochanek, and S. T. Dekosky, “Astrocytes are the major source of nerve growth factor upregulation following traumatic brain injury in the rat,” Experimental Neurology, vol. 149, no. 2, pp. 301–309, 1998. View at Publisher · View at Google Scholar · View at Scopus
  34. N. E. Chorna, L. I. Santiago-Pérez, L. Erb et al., “P2Y2 receptors activate neuroprotective mechanisms in astrocytic cells,” Journal of Neurochemistry, vol. 91, no. 1, pp. 119–132, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Hansson, H. Muyderman, J. Leonova et al., “Astroglia and glutamate in physiology and pathology: aspects on glutamate transport, glutamate-induced cell swelling and gap-junction communication,” Neurochemistry International, vol. 37, no. 2-3, pp. 317–329, 2000. View at Publisher · View at Google Scholar · View at Scopus
  36. R. Dringen, “Metabolism and functions of glutathione in brain,” Progress in Neurobiology, vol. 62, no. 6, pp. 649–671, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. M. E. Gegg, B. Beltran, S. Salas-Pino et al., “Differential effect of nitric oxide on glutathione metabolism and mitochondrial function in astrocytes and neurones: implications for neuroprotection/neurodegeneration?” Journal of Neurochemistry, vol. 86, no. 1, pp. 228–237, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. T. Nakase, G. Söhl, M. Theis, K. Willecke, and C. C. G. Naus, “Increased apoptosis and inflammation after focal brain ischemia in mice lacking connexin43 in astrocytes,” American Journal of Pathology, vol. 164, no. 6, pp. 2067–2075, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. S. Gwak, J. Kang, G. C. Unabia, and C. E. Hulsebosch, “Spatial and temporal activation of spinal glial cells: role of gliopathy in central neuropathic pain following spinal cord injury in rats,” Experimental Neurology, vol. 234, no. 2, pp. 362–372, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Mamczur, B. Borsuk, J. Paszko et al., “Astrocyte-neuron crosstalk regulates the expression and subcellular localization of carbohydrate metabolism enzymes,” Glia, vol. 63, no. 2, pp. 328–340, 2015. View at Publisher · View at Google Scholar
  41. S. Kaneko, T. Maeda, T. Kume et al., “Nicotine protects cultured cortical neurons against glutamate-induced cytotoxicity via alpha7-neuronal receptors and neuronal CNS receptors,” Brain Research, vol. 765, no. 1, pp. 135–140, 1997. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Pacini, L. di Cesare Mannelli, L. Bonaccini, S. Ronzoni, A. Bartolini, and C. Ghelardini, “Protective effect of alpha7 nAChR: behavioural and morphological features on neuropathy,” Pain, vol. 150, no. 3, pp. 542–549, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Bencherif, S. Narla, and M. Stachowiak, “Alpha7 neuronal nicotinic receptor: a pluripotent target for diseases of the central nervous system,” CNS & Neurological Disorders: Drug Targets, vol. 13, no. 5, pp. 836–845, 2014. View at Publisher · View at Google Scholar
  44. S. Shaw, M. Bencherif, and M. B. Marrero, “Janus kinase 2, an early target of α7 nicotinic acetylcholine receptor-mediated neuroprotection against Aβ-(1-42) amyloid,” The Journal of Biological Chemistry, vol. 277, no. 47, pp. 44920–44924, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Kawamata and S. Shimohama, “Stimulating nicotinic receptors trigger multiple pathways attenuating cytotoxicity in models of Alzheimer's and Parkinson's diseases,” Journal of Alzheimer's Disease, vol. 24, supplement 2, pp. 95–109, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. T. Suzuki, I. Hide, A. Matsubara et al., “Microglial α7 nicotinic acetylcholine receptors drive a phospholipase C/IP3 pathway and modulate the cell activation toward a neuroprotective role,” Journal of Neuroscience Research, vol. 83, no. 8, pp. 1461–1470, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. Liu, X. Zeng, Y. Hui et al., “Activation of α7 nicotinic acetylcholine receptors protects astrocytes against oxidative stress-induced apoptosis: implications for Parkinson's disease,” Neuropharmacology, vol. 91, pp. 87–96, 2015. View at Publisher · View at Google Scholar
  48. J. Massagué, S. W. Blain, and R. S. Lo, “TGFβ signaling in growth control, cancer, and heritable disorders,” Cell, vol. 103, no. 2, pp. 295–309, 2000. View at Publisher · View at Google Scholar · View at Scopus
  49. Y. Zhu, B. Ahlemeyer, E. Bauerbach, and J. Krieglstein, “TGF-beta1 inhibits caspase-3 activation and neuronal apoptosis in rat hippocampal cultures,” Neurochemistry International, vol. 38, no. 3, pp. 227–235, 2001. View at Publisher · View at Google Scholar · View at Scopus
  50. K. M. Dhandapani, M. Hadman, L. de Sevilla, M. F. Wade, V. B. Mahesh, and D. W. Brann, “Astrocyte protection of neurons: role of transforming growth factor-β signaling via a c-Jun-AP-1 protective pathway,” The Journal of Biological Chemistry, vol. 278, no. 44, pp. 43329–43339, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. S. M. Wahl, “Transforming growth factor beta (TGF-β) in inflammation: a cause and a cure,” Journal of Clinical Immunology, vol. 12, no. 2, pp. 61–74, 1992. View at Publisher · View at Google Scholar · View at Scopus
  52. K. C. Flanders, R. F. Ren, and C. F. Lippa, “Transforming growth factor-betas in neurodegenerative disease,” Progress in Neurobiology, vol. 54, no. 1, pp. 71–85, 1998. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Schober, R. Hertel, U. Arumäe et al., “Glial cell line-derived neurotrophic factor rescues target-deprived sympathetic spinal cord neurons but requires transforming growth factor-beta as cofactor in vivo,” Journal of Neuroscience, vol. 19, no. 6, pp. 2008–2015, 1999. View at Google Scholar · View at Scopus
  54. N.-F. Chen, S.-Y. Huang, W.-F. Chen et al., “TGF-β1 attenuates spinal neuroinflammation and the excitatory amino acid system in rats with neuropathic pain,” Journal of Pain, vol. 14, no. 12, pp. 1671–1685, 2013. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Echeverry, X. Q. Shi, A. Haw, H. Liu, Z.-W. Zhang, and J. Zhang, “Transforming growth factor-beta1 impairs neuropathic pain through pleiotropic effects,” Molecular Pain, vol. 5, article 16, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. J. J. Letterio and A. B. Roberts, “TGF-β: a critical modulator of immune cell function,” Clinical Immunology and Immunopathology, vol. 84, no. 3, pp. 244–250, 1997. View at Publisher · View at Google Scholar · View at Scopus
  57. J. M. Rubio-Perez and J. M. Morillas-Ruiz, “A review: inflammatory process in Alzheimer's disease, role of cytokines,” The Scientific World Journal, vol. 2012, Article ID 756357, 15 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. T. Gillessen, S. L. Budd, and S. A. Lipton, “Excitatory amino acid neurotoxicity,” Advances in Experimental Medicine and Biology, vol. 513, pp. 3–40, 2002. View at Google Scholar · View at Scopus
  59. E.-S. Y. Lee, M. Sidoryk, H. Jiang, Z. Yin, and M. Aschner, “Estrogen and tamoxifen reverse manganese-induced glutamate transporter impairment in astrocytes,” Journal of Neurochemistry, vol. 110, no. 2, pp. 530–544, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. R. J. Bridges and C. S. Esslinger, “The excitatory amino acid transporters: pharmacological insights on substrate and inhibitor specificity of the EAAT subtypes,” Pharmacology & Therapeutics, vol. 107, no. 3, pp. 271–285, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. S. Bröer and N. Brookes, “Transfer of glutamine between astrocytes and neurons,” Journal of Neurochemistry, vol. 77, no. 3, pp. 705–719, 2001. View at Publisher · View at Google Scholar · View at Scopus
  62. D. W. Choi, M. Maulucci-Gedde, and A. R. Kriegstein, “Glutamate neurotoxicity in cortical cell culture,” Journal of Neuroscience, vol. 7, no. 2, pp. 357–368, 1987. View at Google Scholar · View at Scopus
  63. I. Shaked, I. Ben-Dror, and L. Vardimon, “Glutamine synthetase enhances the clearance of extracellular glutamate by the neural retina,” Journal of Neurochemistry, vol. 83, no. 3, pp. 574–580, 2002. View at Publisher · View at Google Scholar · View at Scopus
  64. P. T. Ohara, J.-P. Vit, A. Bhargava et al., “Gliopathic pain: when satellite glial cells go bad,” Neuroscientist, vol. 15, no. 5, pp. 450–463, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. E. D. Muse, H. Jurevics, A. D. Toews, G. K. Matsushima, and P. Morell, “Parameters related to lipid metabolism as markers of myelination in mouse brain,” Journal of Neurochemistry, vol. 76, no. 1, pp. 77–86, 2001. View at Publisher · View at Google Scholar · View at Scopus
  66. J. Zou, Y.-X. Wang, F.-F. Dou et al., “Glutamine synthetase down-regulation reduces astrocyte protection against glutamate excitotoxicity to neurons,” Neurochemistry International, vol. 56, no. 4, pp. 577–584, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. L. Hertz and T. B. Rodrigues, “Astrocytic-neuronal astrocytic pathway selection for formation and degradation of glutamate/GABA,” Frontiers in Endocrinology, vol. 5, p. 42, 2014. View at Publisher · View at Google Scholar